ArticleAnti-cancer drugs2025

Low-dose anlotinib plus immune checkpoint inhibitors offers better efficacy and safety in advanced non-small cell lung cancer treatment.

Tingfei Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.